Ionis Pharmaceuticals, Inc. ISI.F Stock
Ionis Pharmaceuticals, Inc. Price Chart
Ionis Pharmaceuticals, Inc. ISI.F Financial and Trading Overview
Ionis Pharmaceuticals, Inc. stock price | 39.55 EUR |
Previous Close | 37.63 EUR |
Open | 37.98 EUR |
Bid | 37.99 EUR x 20000 |
Ask | 38.19 EUR x 20000 |
Day's Range | 37.98 - 38.01 EUR |
52 Week Range | 31.06 - 48.17 EUR |
Volume | 25 EUR |
Avg. Volume | 39 EUR |
Market Cap | 5.44B EUR |
Beta (5Y Monthly) | 0.523591 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.38 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 55.82 EUR |
ISI.F Valuation Measures
Enterprise Value | 4.56B EUR |
Trailing P/E | N/A |
Forward P/E | -21.59659 |
PEG Ratio (5 yr expected) | -0.23 |
Price/Sales (ttm) | 9.443041 |
Price/Book (mrq) | 11.172839 |
Enterprise Value/Revenue | 7.911 |
Enterprise Value/EBITDA | -10.144 |
Trading Information
Ionis Pharmaceuticals, Inc. Stock Price History
Beta (5Y Monthly) | 0.523591 |
52-Week Change | 20.79% |
S&P500 52-Week Change | 20.43% |
52 Week High | 48.17 EUR |
52 Week Low | 31.06 EUR |
50-Day Moving Average | 34.28 EUR |
200-Day Moving Average | 38.15 EUR |
ISI.F Share Statistics
Avg. Volume (3 month) | 39 EUR |
Avg. Daily Volume (10-Days) | 41 EUR |
Shares Outstanding | 143.09M |
Float | 142.04M |
Short Ratio | N/A |
% Held by Insiders | 0.73% |
% Held by Institutions | 93.22% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -57.099% |
Operating Margin (ttm) | -80.69% |
Gross Margin | -46.34% |
EBITDA Margin | -77.98% |
Management Effectiveness
Return on Assets (ttm) | -10.75% |
Return on Equity (ttm) | -54.99% |
Income Statement
Revenue (ttm) | 575.97M EUR |
Revenue Per Share (ttm) | 4.05 EUR |
Quarterly Revenue Growth (yoy) | -8.00000000000000000000000000000000% |
Gross Profit (ttm) | -257866000 EUR |
EBITDA | -449144000 EUR |
Net Income Avi to Common (ttm) | -328880000 EUR |
Diluted EPS (ttm) | -2.2 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 2.35B EUR |
Total Cash Per Share (mrq) | 16.45 EUR |
Total Debt (mrq) | 1.36B EUR |
Total Debt/Equity (mrq) | 279.79 EUR |
Current Ratio (mrq) | 9.809 |
Book Value Per Share (mrq) | 3.402 |
Cash Flow Statement
Operating Cash Flow (ttm) | -376712000 EUR |
Levered Free Cash Flow (ttm) | -180147008 EUR |
Profile of Ionis Pharmaceuticals, Inc.
Country | Germany |
State | CA |
City | Carlsbad |
Address | 2855 Gazelle Court |
ZIP | 92010 |
Phone | 760 931 9200 |
Website | https://www.ionispharma.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 796 |
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops Cimdelirsen to inhibit the production of growth hormone receptor; IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. Ionis Pharmaceuticals, Inc. was incorporated in 1989 and is based in Carlsbad, California.
Q&A For Ionis Pharmaceuticals, Inc. Stock
What is a current ISI.F stock price?
Ionis Pharmaceuticals, Inc. ISI.F stock price today per share is 39.55 EUR.
How to purchase Ionis Pharmaceuticals, Inc. stock?
You can buy ISI.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Ionis Pharmaceuticals, Inc.?
The stock symbol or ticker of Ionis Pharmaceuticals, Inc. is ISI.F.
Which industry does the Ionis Pharmaceuticals, Inc. company belong to?
The Ionis Pharmaceuticals, Inc. industry is Biotechnology.
How many shares does Ionis Pharmaceuticals, Inc. have in circulation?
The max supply of Ionis Pharmaceuticals, Inc. shares is 145.75M.
What is Ionis Pharmaceuticals, Inc. Price to Earnings Ratio (PE Ratio)?
Ionis Pharmaceuticals, Inc. PE Ratio is now.
What was Ionis Pharmaceuticals, Inc. earnings per share over the trailing 12 months (TTM)?
Ionis Pharmaceuticals, Inc. EPS is -2.38 EUR over the trailing 12 months.
Which sector does the Ionis Pharmaceuticals, Inc. company belong to?
The Ionis Pharmaceuticals, Inc. sector is Healthcare.